Intestinal and multivisceral transplantation

• Autor(a) principal: Meira Filho,Sérgio Paiva
• Data de Publicação: 2015
• Outros Autores: Guardia,Bianca Della, Evangelista,Andréia Silva, Matielo,Celso Eduardo Lourenço, Neves,Douglas Bastos, Pandullo,Fernando Luis, Felga,Guilherme Eduardo Gonçalves, Alves,Jefferson André da Silva, Curvelo,Lilian Amorim, Diaz,Luiz Gustavo Guedes, Rusi,Marcela Balbo, Viveiros,Marcelo de Melo, Almeida,Marcio Dias de, Epstein,Marina Gabrielle, Pedroso,Pamella Tung, Salvalaggio,Paolo, Meirelles Júnior,Roberto Ferreira, Rocco,Rodrigo Andrey, Almeida,Samira Scalso de, Rezende,Marcelo Bruno de
• Tipo de documento: Artigo
• Idioma: eng
• Título da fonte: Einstein (São Paulo)
• Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082015000100024
• topic: Transplantation; Intestine; small/transplantation; Transplantation chimera; Tissue donors; Transplantation immunology

Intestinal transplantation has shown exceptional growth over the past 10 years. At the end of the 1990’s, intestinal transplantation moved out of the experimental realm to become a routine practice in treating patients with severe complications related to total parenteral nutrition and intestinal failure. In the last years, several centers reported an increasing improvement in survival outcomes (about 80%), during the first 12 months after surgery, but long-term survival is still a challenge. Several advances led to clinical application of transplants. Immunosuppression involved in intestinal and multivisceral transplantation was the biggest gain for this procedure in the past decade due to tacrolimus, and new inducing drugs, mono- and polyclonal anti-lymphocyte antibodies. Despite the advancement of rigid immunosuppression protocols, rejection is still very frequent in the first 12 months, and can result in long-term graft loss. The future of intestinal transplantation and multivisceral transplantation appears promising. The major challenge is early recognition of acute rejection in order to prevent graft loss, opportunistic infections associated to complications, post-transplant lymphoproliferative disease and graft versus host disease; and consequently, improve results in the long run.